Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
Recruiting
N/A
Interventional Study
Coronary Artery Disease
Myocardial Infarction (MI)
CABG
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 24 (estimated)
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged over 18 years old
* Undergoing CABG surgery
Exclusion Criteria:
* Critical left main stem coronary disease
* Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)
* Haemodynamic instability caused by arrhythmia requiring c…
Contacts
No contact information available.